RxDoctor Payments Data

Meyer Abittan, MD

Cardiology · Roslyn, NYNPI 1548248339

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 36.7% of the total. Reporting peaked in 2019 at $17,302 and has fallen 89.9% since, to $1,752 in 2025. Among cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,352in general payments, 2019–2025

Across 542 payments — averaging $52.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$10K
  • Regeneron Healthcare Solutions, Inc.$5K
  • Amgen$2K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$1K
  • plus $8K from 35 others

What the payments were for

  • Speaking & faculty fees$13,62248%
  • Travel & lodging$9113%
  • Food & beverage$13,77849%
  • Education$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,352 in reported general payments places this provider in the 90th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York

Medicare billing

Part B allowed, 2024
$1,878,867
Medicare patients
1,779
Services billed
15,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban244$338,746
XareltoRivaroxaban189$236,565
Repatha SureclickEvolocumab92$81,410
EntrestoSacubitril/Valsartan66$71,604
MultaqDronedarone Hcl38$55,940
FarxigaDapagliflozin Propanediol62$46,162
Inderal LaPropranolol Hcl11$24,866
Rosuvastatin Calcium1,400$24,502
BrilintaTicagrelor24$23,081
LivaloPitavastatin Calcium21$19,856
Ezetimibe541$17,290
Metoprolol Succinate805$15,519
Praluent PenAlirocumab22$14,205
EdarbiAzilsartan Medoxomil23$10,680
Ranolazine ErRanolazine59$8,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,101$338,746244 claims
Johnson & JohnsonXarelto$1,455$236,565189 claims
NovartisEntresto$919$71,60466 claims
AstraZenecaFarxiga, Brilinta$932$69,24386 claims
Sanofi-aventis U.S. LLCMultaq$10,405$55,94038 claims
Kowa Pharmaceuticals America, Inc.Livalo$148$19,85621 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$202$18,47834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 cardiology providers in New York.

Other cardiology in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →